MRNA (Moderna Therapeutics) Earnings per share growth rate in current year

Moderna, Inc. (MRNA) is implementing a global transition toward oncotherapy and new vaccines, as confirmed by the annual EPS change ratio. The value of -3.60 reflects this status. The business relies on the robotization of mRNA synthesis and AI to accelerate testing. However, the sharp decline in revenue following the pandemic has created high volatility, tying future success to the approval of new drugs.

modernatx.com (MRNA): Net earnings per share growth this year from 07/04/2022 to 11/14/2026

Analytical breakdowns and data insights for company Moderna Therapeutics (MRNA)

- current price and projected stock value:

Quote Chart Moderna Corp|MRNA - Analyst Consensus Forecast

- business market valuation indicators:

Market Value Moderna|MRNA - Enterprise Value

- balance sheet equity data:

Accounting Value per Share Moderna|MRNA - Company Net Assets|Market Cap to Book Value Multiple modernatx.com|MRNA - Company Total Assets

- debt burden and liquidity indicators:

- net income and valuation ratios data:

MRNA - Company Net Income|Expected Net Profit Moderna, Inc.|MRNA - P/E Multiple|Price to Future Earnings Ratio Moderna, Inc.|MRNA - PEG Multiple|Company Value to EBITDA Moderna, Inc.|MRNA - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Moderna|MRNA - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months modernatx.com|MRNA - Earnings growth in current year|Earnings growth forecast for next year Moderna, Inc.

- company sales and revenue statistics:

MRNA - Company Sales|Company Future Revenue Moderna Corp|MRNA - P/S Multiple|Market Cap to Expected Sales Ratio Moderna, Inc.

Basic company analysis:Moderna Therapeutics

For Moderna, Inc. (MRNA), the efficiency of its unified mRNA platform and the high speed of scaling new products directly determine the dynamics of net income available to shareholders. Analyzing the rate of change in earnings per share over 12 months allows for an assessment of the annual EPS growth percentage, where a steady upward trend confirms the commercial success of the technological framework and the long-term potential for business capitalization.

Main competitors